Fortress Biotech 8-K: Officer/Director Changes & Comp Arrangements

TL;DR

**Fortress Biotech just filed an 8-K about executive changes and pay, keep an eye on leadership shifts.**

AI Summary

Fortress Biotech, Inc. filed an 8-K on January 26, 2024, reporting an event that occurred on January 25, 2024, related to the departure or election of directors or officers and their compensatory arrangements. This filing indicates potential changes in leadership or executive compensation, which could impact the company's strategic direction and financial health. Investors should pay attention to the details of these changes as they can signal shifts in corporate governance or financial commitments to key personnel, potentially affecting future stock performance.

Why It Matters

Changes in leadership and executive compensation can significantly influence a company's strategy, operational efficiency, and financial stability, directly impacting shareholder value.

Risk Assessment

Risk Level: medium — Changes in executive leadership and compensation can introduce uncertainty regarding future company direction and financial performance, posing a medium risk to investors.

Analyst Insight

Investors should monitor Fortress Biotech's subsequent filings or press releases for specific details regarding the reported executive changes and compensatory arrangements, as these will provide crucial insights into the company's future direction and financial commitments.

Key Players & Entities

• Fortress Biotech, Inc. (company) — the registrant filing the 8-K
• January 25, 2024 (date) — date of the earliest event reported
• January 26, 2024 (date) — date the 8-K was filed
• 001-35366 (other) — Commission File Number
• 20-5157386 (other) — I.R.S. Employer Identification No.

Forward-Looking Statements

• Fortress Biotech will provide more specific details about the executive changes and compensation in a subsequent filing or press release. (Fortress Biotech, Inc.) — medium confidence, target: 2024-03-31

FAQ

Filing Documents

• tm244262d1_8k.htm (8-K) — 30KB
• 0001104659-24-007245.txt ( ) — 241KB
• fbio-20240125.xsd (EX-101.SCH) — 4KB
• fbio-20240125_def.xml (EX-101.DEF) — 26KB
• fbio-20240125_lab.xml (EX-101.LAB) — 36KB
• fbio-20240125_pre.xml (EX-101.PRE) — 25KB
• tm244262d1_8k_htm.xml (XML) — 5KB

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Sections 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2024 Fortress Biotech, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35366 20-5157386 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 1111 Kane Concourse , Suite 301 Bay Harbor Islands , FL 33154 (Address of principal executive offices) Registrant's telephone number, including area code: (781) 652-4500 Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencements communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock FBIO Nasdaq Capital Market 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock FBIOP Nasdaq Capital Market Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers . On January 25, 2024, Eric Rowinsky, M.D., a director currently serving on the board of directors of Fortress Biotech, Inc. (the " Company "), informed the Company that he does not intend to stand for re-election at the Company's 2024 annual meeting of stockholders (the " 2024 Annual Meeting ") due to other professional commitments. Accordingly, Dr. Rowinsky's service on the Company's Board of Directors (the " Board ") will end as of the date of the Company's 2024 Annual Meeting. Dr. Rowinsky has not provided this notification as a result of any disagreement with the Company on any matter, including relating to the Company's operations, policies or practices, and indeed the Company intends to continue engaging Dr. Rowinsky as a consultant following the date of his Board departure. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Fortress Biotech, Inc. (Registrant) By: /s/ Lindsay A. Rosenwald, M.D. Lindsay A. Rosenwald M.D. Chairman, President and Chief Executive Officer Date: January 26, 2024

View Full Filing

View this 8-K filing on SEC EDGAR